New York, July 13, 2026, 09:09 EDT
Agenus Inc. NASDAQ:AGEN surged 59.4% to $5.34 in premarket trading on Monday after agreeing to an $85 million private placement, a stock sale to selected investors, with warrants that could lift gross proceeds to $340 million. Warrants give holders the right to buy additional shares at fixed prices. The move came before the 9:30 a.m. market open, while Nasdaq futures were down about 1%.
The funding matters now because Agenus reported just $35 million of cash at March 31 and raised a further $11.7 million after the quarter. The committed $85 million is equal to roughly 61% of its Friday market value; the full package would be about 2.4 times that value. Yet Agenus says existing cash plus the initial proceeds will fund operations only into the third quarter of 2027. Its runway through 2031 assumes every warrant is exercised.
Trading was already running far ahead of that distinction. About 38.66 million shares had changed hands by 9 a.m., slightly more than the company’s stated public float—the shares readily available for trading—of 37.78 million. That was more than 42 times its 65-day average volume. Short interest, or shares borrowed and sold in a bet on a price decline, stood at 5.99 million shares, equal to 15.87% of the float, on June 30. Short covering may have amplified Monday’s jump.
The transaction splits the cash and dilution across three legs. The common-equivalent figures below count pre-funded warrants as shares because they can be exercised for one cent.
| Funding leg | Gross cash | Potential new shares | Price or exercise price | Main condition |
|---|---|---|---|---|
| Initial placement | $85 million | 23.04 million | $3.69 | Expected to close July 15 |
| Series A warrants | $85 million | 21.14 million | $4.02 | Earlier of five years or 30 days after Agenus reports at least 60 ROBBIN patients dosed |
| Series B warrants | $170 million | 33.80 million | $5.03 | Earlier of five years or 30 days after pathologic-response data from at least 50 treated patients; linked to Series A |
| Total | $340 million | 77.98 million | $4.36 weighted cash per share | Requires full exercise |
Agenus also agreed to give lead investor Commodore Capital two board nominees while it and its affiliates hold at least 5% of the company. The proceeds cannot be used for business development, share buybacks or voluntary early debt repayment, effectively directing the money toward the trial and operating costs.
Agenus had 42.68 million shares outstanding on July 10. The initial placement would lift the common-equivalent count to about 65.72 million; full exercise of all warrants would take it to 120.66 million, or 2.83 times the pre-deal total. Existing investors would then own about 35.4% of the enlarged company, before accounting for other options or convertible securities. At the $5.34 premarket price, the stock was trading above both warrant exercise prices, although holders are not required to exercise.
The capital accompanies a sharp pipeline reset. Agenus will stop funding BATTMAN, a Phase 3 metastatic colorectal-cancer study launched in April, and shift resources to ROBBIN, an 850-patient trial in previously untreated, high-risk Stage II and Stage III microsatellite-stable, or MSS, colon cancer. MSS tumors generally lack the repair defects that make some cancers more visible to immune drugs. ROBBIN will test BOT+BAL before surgery—known as neoadjuvant treatment—with event-free survival, a measure of time without specified disease events, as its primary goal.
Agenus bases the pivot on its NEST and UNICORN Phase 2 studies. The company reported pathologic responses in roughly 60% to 70% of patients, major responses in 35% to 40%, and complete responses in about 30%; a pathologic complete response means no viable tumour is found at surgery. Agenus said treated patients remained disease-free after median follow-up ranging from about nine to 18 months. Chief Medical Officer Steven O’Day said MSS colon cancer “has resisted standard checkpoint inhibitors,” while CEO Garo Armen cited “the strength of the emerging clinical evidence.” SEC
The target population differs from those served by the leading approved colorectal-cancer checkpoint drugs.
| Company and programme | Target population | U.S. position |
|---|---|---|
| Agenus BOT+BAL | High-risk Stage II/III MSS colon cancer, before surgery | Planned Phase 3; first patient expected in Q1 2027 |
| Bristol Myers Squibb NYSE:BMY, Opdivo plus Yervoy | Unresectable or metastatic MSI-H/dMMR colorectal cancer | FDA-approved combination |
| Merck & Co. NYSE:MRK, Keytruda | Unresectable or metastatic MSI-H/dMMR colorectal cancer | FDA-approved |
MSI-H/dMMR cancers have defects in DNA repair and are more likely to respond to checkpoint therapy. Agenus is trying to extend that approach to the much larger MSS population and at an earlier, potentially curative stage.
But most of the advertised financing is not yet cash. Another $255 million depends on warrant exercise, ROBBIN has not dosed its first patient, and early pathologic responses from small studies may not translate into longer event-free survival in an 850-patient trial. Slower enrolment, unexpected toxicity, failure to improve outcomes or a share-price fall below the warrant strikes could leave Agenus with a runway ending in 2027 and another capital requirement. Full exercise, meanwhile, would reduce existing holders’ percentage ownership by about 65%.
The first ROBBIN patient is expected in the first quarter of 2027, with interim pathologic-response data in the second half of that year. The interim event-free-survival analysis is not due until the second half of 2029. Monday’s surge therefore prices in two linked bets: that the clinical pivot works, and that Agenus keeps its shares high enough for the contingent financing to arrive.
